The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
NCI 8609: Interim fluoro-3’-deoxythymidine (FLT) PET imaging findings from the phase I trial of PARP inhibitor veliparib (V) and carboplatin (C) in advanced breast cancer.
Bhuvaneswari Ramaswamy
No relevant relationships to disclose
Jun Zhang
No relevant relationships to disclose
Nathan Hall
No relevant relationships to disclose
Katharina Schregel
No relevant relationships to disclose
Maryam B. Lustberg
No relevant relationships to disclose
Robert Wesolowski
No relevant relationships to disclose
Ewa Mrozek
No relevant relationships to disclose
Rachel M. Layman
No relevant relationships to disclose
Erin Macrae Olson
No relevant relationships to disclose
Susan Ottman
No relevant relationships to disclose
Andrea Camp
No relevant relationships to disclose
Jeffrey J. Chalmers
No relevant relationships to disclose
Susan Michelle Geyer
No relevant relationships to disclose
Miguel Angel Villalona-Calero
No relevant relationships to disclose
Charles L. Shapiro
No relevant relationships to disclose
Michael R. Grever
No relevant relationships to disclose
Michael V. Knopp
No relevant relationships to disclose